logo.jpg
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
February 21, 2024 08:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
logo.jpg
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
January 18, 2024 07:45 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
logo.jpg
Processa Pharmaceuticals to Present at the Biotech Showcase 2024
January 02, 2024 17:06 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
logo.jpg
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
December 19, 2023 09:00 ET | Processa Pharmaceuticals, Inc.
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved...
logo.jpg
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
November 29, 2023 08:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next...
logo.jpg
Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 08:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...